18 December 2015
But don't expect to be able to buy a fancy electric sports car just yet. The local office will reportedly focus on selling industrial-scale batteries to industry.
Elon Musk’s Tesla Motors looks set to establish its first presence in South Africa, it was reported on Friday.
Htxt.africa reported that Tesla is planning to set up a local office early in the new year. The plan is not to sell Tesla’s high-end electric cars in South Africa — not yet, at least — but rather the company’s energy storage solutions.
According to Htxt, the office will be run by Evan Rice, who has been CEO of renewable Western Cape-based energy specialist GreenCape for the past three years. He will be Tesla’s sole employee in South Africa, at least for now.
The local office will reportedly sell Tesla’s Powerpack battery systems, which are aimed at industrial applications.
Tesla Powerpack is described as a utility-scale rechargeable lithium-ion battery that is designed to store energy off the grid. Designed in a modular way, multiple units can be connected, creating capacities that in theory could power entire cities.
The Powerpack is effectively an industrial version of Tesla’s Powerwall, a battery solution for use in the home and in small businesses announced by Musk in April 2015. A number of local distributors already offer the Powerwall to South African consumers.
You must be the widely publicized Goof Ball that Shorted the stock and lost $100,000 in his 401k in the process and tried to get people to donate money and bail him out.
MHR is #1, the lowest of the low and buying the company bonds was a job terminating decision made by the Third Avenue Fund former CEO, David Barse, who was fired because of his poor judgment and reckless stupidity.
That is how bad this company is.
You are a Long Bozo.
The broader market is in a Bear Market, with many small company stocks being down 25% to 50%. That being said, I believe that analysts and investors will be looking for the numbers on the bottom line during the next several months resulting from the recent approvals / deals.
“New treatments that safely and effectively attenuate insulin-induced hypoglycemia are needed for patients with congenital hyperinsulinism, as well as other diseases that cause hypoglycemia due to high insulin levels. There are no approved medications, and those currently used have inconsistent efficacy and issues with tolerability. Currently disease management options are limited to continuous ingestion or infusion of glucose or surgical removal of part or all of the pancreas... We are developing XOMA 358 as a first-in-class therapeutic for patients with this potentially fatal disease, and we are pleased to be conducting this study at a world-class medical center recognized for its leadership in treating HI patients.”
So far, everything we've heard about XOMA 358 suggests that the drug is likely to be approved by the FDA. With that said, when the Phase 3 trial comes to an end and results are released, I'm expecting the stock to skyrocket. Following this, submission to and approval by the FDA are also likely to lead to massive growth on the stock. With that said, I think we've hit a bottom point with regard to the downward movement, making now a great time to get in on this stock.
December 3, 2015
While XOMA Corp hasn't necessarily been at the top of its game since the early 2000's, I believe that this is likely to change, and in a big way. In fact, I believe that XOMA is ripe for the picking at the moment. Today, we'll talk about why I believe that XOMA is headed for gains in the near future.
Impressive Results On XOMA 358 Spell Gains To Come
When XOMA 358 trials first started, I was hopeful, but not sold. However, as we move further and further through the clinical trials on the drug, it is becoming more and more exciting to watch. XOMA 358 is a fully human allosteric monoclonal antibody that was designed to reduce insulin receptor activity. It is hoped that the drug will prove to be a solid treatment for hyperinsulinism (HI) which is a genetic disorder that causes beta cells of the pancreas to secrete excessive insulin. Ultimately, this causes hypoglycemia leading to brain damage and in rare cases, death. Through the studies that have been conducted on XOMA 358, we have seen overwhelmingly impressive results.
Not only did the Phase 1 study prove that the drug had high tolerability, the Phase 2 study showed that XOMA 358 was effective and safe! Now, we're in the midst of the Phase 3 study, which ties everything together with a pretty little bow for the New Drug Application with the United States Food and Drug Administration. In a statement with regard to the initiation of the Phase 3 study into XOMA 358, Paul Rubin, M.D., the company's CEO had the following to say...
December 9, 2015 5:05 PM EST
XOMA (NASDAQ: XOMA) disclosed the following on Wednesday:
On December 3, 2015, XOMA (US) LLC (the “Company” or “XOMA”), as a successor-in-interest of XOMA Ireland Limited and Pfizer Inc. (“Pfizer”), entered into a settlement and amended license agreement (the “Agreement”), pursuant to which XOMA granted a fully-paid, royalty-free, worldwide, irrevocable, non-exclusive license rights to XOMA’s patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products for an upfront, non-dilutive cash payment by Pfizer of $3.8 million in full satisfaction of all obligations to XOMA under the 2007 Agreement (defined below), including but not limited to potential milestone, royalty and other fees under the 2007 Agreement.
Under the terms of the original License Agreement, effective as of August 27, 2007, by and between XOMA Ireland Limited and Pfizer Inc. (the “2007 Agreement”), XOMA received an upfront, non-dilutive cash payment of $30 million and was eligible for potential milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development.
The description of the Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the period ending December 31, 2015.